RxDoctor Payments Data

Brittney Vestal

Family · Bristol, TNNPI 1598777260

Payments from drug & device makers

$4,343in general payments, 2019–2025

Across 272 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$837
  • Novo Nordisk$648
  • GSK$545
  • Corium, LLC$471
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$284
  • Mayne Pharma Commercial LLC$215
  • plus $1K from 32 others

What the payments were for

  • Food & beverage$4,343100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,343 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$51,124
Medicare patients
207
Services billed
916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$93,947
EliquisApixaban101$75,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$42,662
MounjaroTirzepatide33$31,771
RexultiBrexpiprazole11$23,440
LinzessLinaclotide16$21,309
VraylarCariprazine Hcl12$20,116
TradjentaLinagliptin12$6,935
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen221$6,511
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen131$3,905
Dexlansoprazole DrDexlansoprazole11$2,561
SynthroidLevothyroxine Sodium25$2,482
Albuterol Sulfate HfaAlbuterol Sulfate83$2,197
LantusInsulin Glargine,hum.Rec.Anlog11$2,067
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,065

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$648$93,94770 claims
PfizerEliquis$40$75,424101 claims
AbbVieLinzess, Vraylar, Synthroid$837$43,90853 claims
GSKTrelegy Ellipta$545$42,66260 claims
Lilly USA, LLCMounjaro$151$31,77133 claims
Otsuka America Pharmaceutical, Inc.Rexulti$18$23,44011 claims
Boehringer IngelheimTradjenta$24$6,93512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →